These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 33470741)

  • 1. Antibody Development in Patients Treated Long-Term With OnabotulinumtoxinA for Benign Essential Blepharospasm and Hemifacial Spasm.
    Czyz CN; Burns JA; Bergstrom RE
    J Neuroophthalmol; 2021 Dec; 41(4):e684-e687. PubMed ID: 33470741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm.
    Cannon PS; MacKenzie KR; Cook AE; Leatherbarrow B
    Clin Exp Ophthalmol; 2010 Oct; 38(7):688-91. PubMed ID: 20456439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome.
    Czyz CN; Burns JA; Petrie TP; Watkins JR; Cahill KV; Foster JA
    Am J Ophthalmol; 2013 Jul; 156(1):173-177.e2. PubMed ID: 23541393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the injection botulinum toxin A in cases of blepharospasm syndrome, hemifacial spasm and Meige's syndrome.
    Bastola P; Chaudhary M; Agrawal JP; Shah DN
    Kathmandu Univ Med J (KUMJ); 2010; 8(31):305-10. PubMed ID: 22610735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
    Ababneh OH; Cetinkaya A; Kulwin DR
    Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of Injection Botulinum Toxin in Blepharospasm.
    Amatya M; Limbu B; Sthapit PR; Gurung HB; Saiju R
    Nepal J Ophthalmol; 2021 Jan; 13(25):40-49. PubMed ID: 33981096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques.
    Lolekha P; Choolam A; Kulkantrakorn K
    Neurol Sci; 2017 Nov; 38(11):2031-2036. PubMed ID: 28884242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increase lipid tear thickness after botulinum neurotoxin A injection in patients with blepharospasm and hemifacial spasm.
    Ho RW; Fang PC; Chao TL; Chien CC; Kuo MT
    Sci Rep; 2018 May; 8(1):8367. PubMed ID: 29849166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tear meniscus, corneal topographic and aberrometric changes after botulinum toxin-a injection in patients with blepharospasm and hemifacial spasm.
    Bayraktar Bilen N; Bilen Ş; Topçu Yılmaz P; Evren Kemer Ö
    Int Ophthalmol; 2022 Aug; 42(8):2625-2632. PubMed ID: 35355169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of Hemorrhagic Side Effects of Botulinum Neurotoxin Treatment in Patients with Blepharospasm and Hemifacial Spasm on Antithrombotic Medication.
    Wenninger FC; Wabbels B
    Toxins (Basel); 2022 Nov; 14(11):. PubMed ID: 36356019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Essential blepharospasm and hemifacial spasm: characteristic of the patient, botulinum toxin A treatment and literature review].
    Schellini SA; Matai O; Igami TZ; Padovani CR; Padovani CP
    Arq Bras Oftalmol; 2006; 69(1):23-6. PubMed ID: 16491229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of blepharospasm and Meige's syndrome with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice.
    Jochim A; Meindl T; Huber C; Mantel T; Zwirner S; Castrop F; Haslinger B
    J Neurol; 2020 Jan; 267(1):267-275. PubMed ID: 31630241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life in hemifacial spasm patient after treatment with botulinum toxin A; a 24-week, double-blind, randomized, cross-over comparison of Dysport and Neuronox study.
    Kongsengdao S; Kritalukkul S
    J Med Assoc Thai; 2012 Mar; 95 Suppl 3():S48-54. PubMed ID: 22619887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Which factors impact on quality of life for adults with blepharospasm and hemifacial spasm?
    Lawes-Wickwar S; McBain H; Hirani SP; Hurt CS; Dunlop N; Solly D; Crampton B; Newman SP; Ezra DG
    Orbit; 2021 Apr; 40(2):110-119. PubMed ID: 32116098
    [No Abstract]   [Full Text] [Related]  

  • 15. A patient-initiated treatment model for blepharospasm and hemifacial spasm: a randomized controlled trial.
    Lawes-Wickwar S; McBain H; Brini S; Hirani SP; Hurt CS; Flood C; Dunlop N; Solly D; Crampton B; Newman SP; Ezra DG
    BMC Neurol; 2022 Mar; 22(1):99. PubMed ID: 35300599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Alleviating Maneuvers for Periocular Facial Dystonias.
    Kilduff CL; Casswell EJ; Salam T; Hersh D; Ortiz-Perez S; Ezra D
    JAMA Ophthalmol; 2016 Nov; 134(11):1247-1252. PubMed ID: 27606483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Grey Matter Microstructural Integrity Alterations in Blepharospasm Are Partially Reversed by Botulinum Neurotoxin Therapy.
    Alexandru H; Muthuraman M; Chirumamilla VC; Koirala N; Paktas B; Deuschl G; Zeuner KE; Groppa S
    PLoS One; 2016; 11(12):e0168652. PubMed ID: 27992533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.
    Cillino S; Raimondi G; Guépratte N; Damiani S; Cillino M; Di Pace F; Casuccio A
    Eye (Lond); 2010 Apr; 24(4):600-7. PubMed ID: 19648904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Safety and Dosing of OnabotulinumtoxinA: A Prospective, Observational Study.
    Wein T; Jog M; Bhogal M; Dhani S; Miller R; Ismail F; Beauchamp R; Trentin G
    Can J Neurol Sci; 2019 Nov; 46(6):742-752. PubMed ID: 31256770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of preferences between onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm.
    Chundury RV; Couch SM; Holds JB
    Ophthalmic Plast Reconstr Surg; 2013; 29(3):205-7. PubMed ID: 23552607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.